-
Annual Review: Clinical Progress and Future Trends of Breast Cancer
Time of Update: 2022-02-20
Deputy Chairman of YBCSG and Professor Liu Shu from the Affiliated Hospital of Guizhou Medical University made an in-depth interpretation of the cutting-edge research related to the annual academic keyword PI3K inhibitor (PI3Ki) and prospected the new trend of endocrine diagnosis and treatment.
-
Express one-step transformation of 4 types of cells, delivery of 5 types of mRNA, innovative solid tumor cell therapy into the clinic
Time of Update: 2022-02-20
▎WuXi AppTec Content Team Editor On January 24, 2022, SQZ Biotechnologies announced that the US FDA has approved its IND application for a Phase 1/2 clinical trial of its mRNA-based cell therapy SQZ-eAPC-HPV .
-
Express delivery unlimited cancer therapy, Zhijian Jinrui Bio's second-generation RET inhibitor was approved for clinical use in the United States
Time of Update: 2022-02-20
(hereinafter referred to as "Zhijian Jinrui Company") announced that its self-developed second-generation RET inhibitor APS03118 clinical trial application ( IND) has been approved by the US FDA .
-
those stress responses in tumors
Time of Update: 2022-02-20
These changes trigger a persistent state of ER stress (endoplasmic reticulum stress, characteristic: accumulation of misfolded or unfolded proteins) that has been shown to control multiple tumor-promoting properties in cancer cells while dynamically Reprogramming the function of innate and adaptive immune cells .
-
Nuggets innovative drug Betta Pharmaceuticals' oral small-molecule PD-L1 inhibitor was approved for clinical use
Time of Update: 2022-02-20
Betta Pharmaceuticals stated in the announcement that compared with PD-1/PD-L1 antibody drugs, oral small-molecule PD-L1 inhibitors may have similar clinical benefits, and are convenient to take, lower in production costs, and more accessible.
-
HER2-ADC, CDK4/6i, PARPi... Interpretation of annual academic keywords of breast cancer
Time of Update: 2022-02-20
Vice Chairman of YBCSG and Professor Luo Ting from West China Hospital of Sichuan University deeply interprets the progress of HER2-ADC in the field of breast cancer treatment.
-
Cancers: Transarterial radioembolization (TARE) is safe and effective in the treatment of unresectable hepatocellular carcinoma (HCC)
Time of Update: 2022-02-20
A multicenter study from Korea evaluating long-term clinical outcomes of hepatocellular carcinoma (HCC) patients treated with TARE was recently published in Cancers .
A multicenter study from Korea evaluating long-term clinical outcomes of hepatocellular carcinoma (HCC) patients treated with TARE was recently published in Cancers .
-
The clinical results of the express dual mechanism PD-L1 monoclonal antibody are positive, and it is expected to submit a regulatory application to the FDA by the end of the year
Time of Update: 2022-02-20
▎WuXi AppTec Content Team Editor On January 25, 2022, Checkpoint Therapeutics announced that the anti-PD-L1 antibody cosibelimab has achieved positive results in a clinical trial that supports registration .
"Reference: [1] Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma.
-
Express treatment of solid tumors, TCR cell therapy with stem cell characteristics enters the clinic
Time of Update: 2022-02-20
S. FDA has approved the IND application for a Phase 1 clinical trial of the investigational T cell receptor (TCR) therapy LYL132 for the treatment of New York esophageal squamous cell carcinoma patients with solid tumors with neoplasm 1 (NY-ESO-1) antigen .
-
First-line treatment of savatinib in patients with advanced lung sarcomatoid carcinoma, with rapid onset and 7-month PFS
Time of Update: 2022-02-20
The 2021 edition of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer pointed out that for patients with advanced NSCLC, it is recommended to detect genes such as MET amplification and MET exon 14 skipping mutations.
-
"The Lancet-Oncology": What about PD-(L)1 resistance in NSCLC patients?
Time of Update: 2022-02-20
Previous studies have confirmed that the combination of PD(L)-1 inhibitors and CTLA-4 inhibitors shows synergy and has been used for first-line treatment of metastatic non-small cell lung cancer (NSCLC) .
-
Oncolytic virus loaded with CTLA-4 shows positive efficacy in mouse model
Time of Update: 2022-02-20
The paper, titled "Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors" provides in vivo evidence in mice that vectorized anti-CTLA-4 antibodies are intratumoral Delivery can improve safety by reducing systemic exposure .
-
Nature Review Series Han Leng/Jing Ying's research group summarizes the use of big data to carry out research on key scientific issues of immune-related adverse reactions induced by immunotherapy
Time of Update: 2022-02-20
In view of the above research difficulties, on January 17, 2022, Professor Han Leng of Texas A&M University and Associate Researcher Jing Ying of the Clinical Research Center of Shanghai Jiaotong University School of Medicine published a paper entitled Harnessing big data to characterize in the journal Nature Reviews Clinical Oncology The article on immune-related adverse events summarizes and expounds how to maximize the use of multi-dimensional big data for irAE research .
-
This new drug has a disease control rate of up to 100% for pancreatic cancer; natural killer cell therapy is expected to be the first-line treatment for advanced gastric cancer.
Time of Update: 2022-02-20
*Only for medical professionals to read and reference for 1 minute a day, to give you professional "talks" in the tumor circle! (If you need the original text, you can add the editor's WeChat yxj_onc
-
Professor Hu Jie: Treatment of advanced NSCLC - PD-(L)1 is the cornerstone K drug is the best choice
Time of Update: 2022-02-20
➤ At the 2021 World Conference on Lung Cancer (WCLC), Professor Cheng Ying of Jilin Cancer Hospital, as the lead PI of the KEYNOTE-407 China extension study, reported the final analysis results of the study: Among the 125 patients enrolled, drug K The combination therapy group showed a sustained OS benefit, with a 2-year OS rate of 56.
-
For the treatment of brain metastases from breast cancer, which is stronger small molecule TKI vs macromolecule monoclonal antibody?
Time of Update: 2022-02-20
Recently, a study investigating the activity and safety of pyrotinib combined with capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases was published in THE LANCET ONCOLOGY.
-
J Clin Oncol: The addition of carboplatin or bevacizumab to neoadjuvant chemotherapy for triple-negative breast cancer does not improve long-term outcomes (LTOs)
Time of Update: 2022-02-20
The aim was to investigate whether the addition of carboplatin or bevacizumab to weekly paclitaxel (wP) in combination with AC (doxorubicin and cyclophosphamide) significantly improved pathological complete responses in stage II-III triple-negative breast cancer ( pCR) rate and improve long-term outcomes (LTOs) of patients .
-
Fudan University Joint Research Team AS: Brain Glioma Surgical Navigation System for Locating the "Metabolic Boundary" of Tumors
Time of Update: 2022-02-20
Recently, a joint research team of Professor Li Cong from the School of Pharmacy of Fudan University, Researcher Zhang Xiaoyong from the Institute of Brain-inspired Intelligence Science and Technology, Professor Yu Jinhua from the School of Information Science and Technology, and Professor Mao Ying from the Department of Neurosurgery of the Huashan Hospital Affiliated Huashan Hospital has constructed a new type of surface-enhanced Raman scattering based on surface-enhanced Raman scattering.
-
Ther Adv Med Oncol: Real-World Data Study of Treatment and Prognosis in Young (≤40 Years) Patients with Newly Diagnosed Metastatic Female Breast Cancer
Time of Update: 2022-02-20
Compared with patients aged 41-69 years, younger women had more grade III tumors (49% vs 35.
Compared with patients aged 41-69 years, younger women had more grade III tumors (49% vs 35.
-
After PD-(L)1 and CTLA-4 inhibitors, another immune checkpoint inhibitor is here!
Time of Update: 2022-02-20
Secondly, this study provides a new treatment regimen of "LAG-3+PD-1 monoclonal antibody" for newly-treated advanced melanoma patients, making this regimen a new option after PD-1 and PD-1+CTLA4 monoclonal antibody.
